Daratumumab is effective in the relapsed or refractory systemic light‐chain amyloidosis but associated with high infection burden in a frail real‐life populationZoé Van de Wyngaert, Eileen M. Boyle, Michèle Vasseur et al.|British Journal of Haematology|2019Cited by 29
Efficacy and Safety of Daratumumab in a Frail Real-Life Relapsed or Refractory Systemic Light-Chain Amyloidosis Population (AL): Report on 15 Cases from the North of FranceZoé Van de Wyngaert, Eileen M. Boyle, Benjamin Carpentier et al.|Blood|2018Cited by 6
Case Report: Two Cases of Cryptosporidiosis in Heavily Pretreated Patients With MyelomaJordane Demonchy, Eileen M. Boyle, Camille Cordier et al.|Clinical Lymphoma Myeloma & Leukemia|2021Cited by 5